Thermo Fisher Scientific (TMO) said Wednesday it will acquire Sanofi's (SNY) sterile manufacturing facility in Ridgefield, New Jersey.

It will continue producing Sanofi's therapies at the site while expanding capacity for other pharma and biotech clients seeking US-based manufacturing, the company said.

The state-of-the-art fill-finish plant employs more than 200 people, who will join its team following the transaction's expected close in H2, Thermo Fisher said.

The facility will add to Thermo Fisher's existing US network, including sites in North Carolina and Massachusetts, supporting its CDMO and CRO offerings, it said.

The company also said the site will be integrated into its pharma services business under the Laboratory Products and Biopharma Services segment.